Jason Raleigh Nunn
CIK: 0001444319
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Discretionary Trading P&L
Holdings
Transaction History (12 total)
- Sep 2, 2026ADXN
Addex Therapeutics Ltd.
Disposition(D)Direct219.6K shares- - Sep 2, 2026ADXN
Addex Therapeutics Ltd.
Award(A)Direct219.6K shares- - Jun 15, 2026ZBIO
Zenas BioPharma, Inc.
Award(A)DirectStock Option (Right to Buy)
18.5K shares- - Oct 9, 2025ZBIO
Zenas BioPharma, Inc.
Purchase(P)Indirect63.2K shares at avg. $19.00$1.2M - Jun 25, 2025RGLS
Regulus Therapeutics Inc.
Disposition(D)Direct62.5K shares- - Jun 10, 2025ZBIO
Zenas BioPharma, Inc.
Award(A)DirectStock Option (Right to Buy)
18.5K shares- - Apr 30, 2025RGLS
Regulus Therapeutics Inc.
Award(A)Direct62.5K shares- - Sep 16, 2024ZBIO
Zenas BioPharma, Inc.
Purchase(P)Indirect441.2K shares at avg. $17.00$7.5M - Sep 16, 2024ZBIO
Zenas BioPharma, Inc.
Conversion(C)Indirect1.5M shares- - Sep 16, 2024ZBIO
Zenas BioPharma, Inc.
Purchase(P)Indirect441.2K shares at avg. $17.00$7.5M - Sep 16, 2024ZBIO
Zenas BioPharma, Inc.
Conversion(C)Indirect669.1K shares- - Sep 12, 2024ZBIO
Zenas BioPharma, Inc.
Award(A)DirectStock Option (Right to Buy)
37K shares-
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Sep 2, 2026 |  ADXN Addex Therapeutics Ltd. | Disposition(D) | 219,561 | - | $0 | Direct |
| Sep 2, 2026 | ADXN Addex Therapeutics Ltd. | Award(A) | 219,561 | - | $0 | Direct |
| Jun 15, 2026 |  ZBIO Zenas BioPharma, Inc. | Award(A) Stock Option (Right to Buy) | 18,500 | - | - | Direct |
| Oct 9, 2025 | ZBIO Zenas BioPharma, Inc. | Purchase(P) | 63,158 | $19.00 | $1,200,002 | Indirect |
| Jun 25, 2025 |  RGLS Regulus Therapeutics Inc. | Disposition(D) | 62,500 | - | - | Direct |
| Jun 10, 2025 | ZBIO Zenas BioPharma, Inc. | Award(A) Stock Option (Right to Buy) | 18,500 | - | - | Direct |
| Apr 30, 2025 | RGLS Regulus Therapeutics Inc. | Award(A) | 62,500 | - | - | Direct |
| Sep 16, 2024 | ZBIO Zenas BioPharma, Inc. | Purchase(P) | 441,176 | $17.00 | $7,499,992 | Indirect |
| Sep 16, 2024 | ZBIO Zenas BioPharma, Inc. | Conversion(C) | 1,505,388 | - | $0 | Indirect |
| Sep 16, 2024 | ZBIO Zenas BioPharma, Inc. | Purchase(P) | 441,176 | $17.00 | $7,499,992 | Indirect |
| Sep 16, 2024 | ZBIO Zenas BioPharma, Inc. | Conversion(C) | 669,061 | - | $0 | Indirect |
| Sep 12, 2024 | ZBIO Zenas BioPharma, Inc. | Award(A) Stock Option (Right to Buy) | 37,000 | - | - | Direct |
1-12 of 12 transactions
About Nunn Jason Raleigh
Nunn Jason Raleigh (SEC CIK 0001444319) files insider reports with the SEC as Director of Addex Therapeutics Ltd. (ADXN), Director of Zenas BioPharma, Inc. (ZBIO) and Director of Regulus Therapeutics Inc. (RGLS).
Signal8 holds 9 ownership filings by Nunn Jason Raleigh (2 Form 3, 7 Form 4), filed between Sep 12, 2024 and Sep 4, 2026. Those filings report 12 transactions, from Sep 12, 2024 to Sep 2, 2026. Signal8's Form 4 history starts in Sep 2024.
The business address on Nunn Jason Raleigh's filings is in GENEVA.
Recent filings by Nunn Jason Raleigh
- Sep 2, 2026: Disposition to issuer transaction of ADXN shares (Form 4, code D).
- Sep 2, 2026: Grant or award of ADXN shares (Form 4, code A).
- Jun 15, 2026: Grant or award of ZBIO derivative securities (Form 4, code A).
- Oct 9, 2025: Open-market purchase of ZBIO shares (Form 4, code P).
- Jun 25, 2025: Disposition to issuer transaction of RGLS shares (Form 4, code D).
Other insiders filing for Addex Therapeutics Ltd. (ADXN)
- Teyssedou Lenaic Nathanael, PRINCIPAL ACCOUNTING OFFICER
- Kalinichev Mikhail, HEAD OF TRANSLATIONAL SCIENCE
- Mills Roger, CHIEF MEDICAL OFFICER
- Manke Isaac, Director
- Lawton Vincent Michael, Director
- Hill Raymond George, Director